Stock LUN LUNDBECK
Add to a list
To use this feature you must be a member
Log inSign up

Financials Lundbeck Nasdaq Copenhagen

Equities

LUN

DK0061804697

Pharmaceuticals

Market Closed - Nasdaq Copenhagen
Other stock markets
 11:20:00 2024-07-12 am EDT 		5-day change 1st Jan Change
34.95 DKK -1.55% Intraday chart for Lundbeck +2.19% +1.19%
Jun. 26 Otsuka and Lundbeck's PTSD Treatment Moves Forward as FDA Accepts New Drug Application MT
Jun. 25 US FDA Accepts Lundbeck, Otsuka's New Drug Application for PTSD Combo Treatment MT

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 25,433 31,719 38,725 - -
Enterprise Value (EV) 1 27,464 31,008 34,320 30,635 26,524
P/E ratio 13.5 x 14.2 x 13.1 x 11.3 x 10.2 x
Yield 2.23% 2.14% 2.23% 2.57% 3.02%
Capitalization / Revenue 1.39 x 1.59 x 1.84 x 1.74 x 1.68 x
EV / Revenue 1.51 x 1.56 x 1.63 x 1.38 x 1.15 x
EV / EBITDA 5.89 x 5.49 x 5.69 x 4.71 x 3.79 x
EV / FCF 10.2 x 8.66 x 7.87 x 6.61 x 5.25 x
FCF Yield 9.83% 11.5% 12.7% 15.1% 19.1%
Price to Book 1.24 x 1.47 x 1.61 x 1.44 x 1.29 x
Nbr of stocks (in thousands) 992,840 992,840 992,011 - -
Reference price 2 26.05 32.76 40.06 40.06 40.06
Announcement Date 2/7/23 2/7/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 17,036 17,672 16,299 18,246 19,912 21,097 22,211 23,061
EBITDA 1 4,823 4,783 3,720 4,663 5,652 6,030 6,506 7,007
EBIT 1 3,608 1,990 2,010 2,852 3,195 4,096 4,957 5,500
Operating Margin 21.18% 11.26% 12.33% 15.63% 16.05% 19.42% 22.32% 23.85%
Earnings before Tax (EBT) 1 3,481 1,906 1,581 2,474 2,993 4,152 4,711 5,373
Net income 1 2,667 1,581 1,318 1,916 2,290 3,075 3,456 3,879
Net margin 15.66% 8.95% 8.09% 10.5% 11.5% 14.57% 15.56% 16.82%
EPS 2 - - - 1.930 2.310 3.060 3.547 3.943
Free Cash Flow 1 2,169 3,360 1,662 2,699 3,579 4,361 4,637 5,055
FCF margin 12.73% 19.01% 10.2% 14.79% 17.97% 20.67% 20.88% 21.92%
FCF Conversion (EBITDA) 44.97% 70.25% 44.68% 57.88% 63.32% 72.32% 71.28% 72.14%
FCF Conversion (Net income) 81.33% 212.52% 126.1% 140.87% 156.29% 141.82% 134.19% 130.32%
Dividend per Share 2 - - - 0.5800 0.7000 0.8945 1.028 1.209
Announcement Date 2/6/20 2/4/21 2/9/22 2/7/23 2/7/24 - - -
1DKK in Million2DKK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 4,053 4,372 4,475 4,719 4,680 5,044 4,938 4,952 4,978 5,288 5,255 5,347 5,278 5,345 5,442
EBITDA 1 440 1,290 1,049 1,414 910 1,845 1,493 1,521 793 1,746 1,548 1,641 1,317 1,936 2,255
EBIT 1 6 875 622 952 403 1,233 840 891 231 1,278 1,258 1,334 984.5 1,489 1,781
Operating Margin 0.15% 20.01% 13.9% 20.17% 8.61% 24.44% 17.01% 17.99% 4.64% 24.17% 23.95% 24.94% 18.65% 27.86% 32.73%
Earnings before Tax (EBT) 1 -112 528 647 882 417 1,150 785 883 175 1,307 1,045 1,111 852.3 1,528 1,791
Net income 1 -2 412 505 688 311 880 600 676 134 1,006 794.5 840 507.5 1,192 1,397
Net margin -0.05% 9.42% 11.28% 14.58% 6.65% 17.45% 12.15% 13.65% 2.69% 19.02% 15.12% 15.71% 9.61% 22.3% 25.67%
EPS 2 - - 0.5100 0.6900 0.3100 0.8900 0.6000 0.6800 0.1400 1.010 0.7901 0.8435 0.5252 1.200 1.410
Dividend per Share 2 - - - - 0.5800 - - - 0.7000 - - - 0.4810 - -
Announcement Date 2/9/22 5/11/22 8/17/22 11/9/22 2/7/23 5/10/23 8/16/23 11/8/23 2/7/24 5/15/24 - - - - -
1DKK in Million2DKK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 6,625 3,966 3,043 2,031 - - - -
Net Cash position 1 - - - - 711 4,405 8,090 12,200
Leverage (Debt/EBITDA) 1.374 x 0.8292 x 0.818 x 0.4356 x - - - -
Free Cash Flow 1 2,169 3,360 1,662 2,699 3,579 4,361 4,637 5,055
ROE (net income / shareholders' equity) 26.8% 9.37% 14.2% 16.4% 10.7% 16.2% 15.5% 15.6%
ROA (Net income/ Total Assets) 13.2% 4.4% 7.07% 8.87% 6.12% 8% 8.41% 8.43%
Assets 1 20,266 35,893 18,647 21,606 37,429 38,439 41,069 46,036
Book Value Per Share 2 - - - 20.90 22.20 24.90 27.80 31.00
Cash Flow per Share 2 - - - 3.540 4.110 4.720 5.210 5.270
Capex 1 440 477 610 820 501 432 554 475
Capex / Sales 2.58% 2.7% 3.74% 4.49% 2.52% 2.05% 2.5% 2.06%
Announcement Date 2/6/20 2/4/21 2/9/22 2/7/23 2/7/24 - - -
1DKK in Million2DKK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Lundbeck

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
40.06 DKK
Average target price
39.96 DKK
Spread / Average Target
-0.25%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
MCKESSON CORPORATION Stock McKesson Corporation
+24.55% 74.8B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
-6.59% 22.92B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+14.17% 8.74B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
-2.89% 7.94B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-33.14% 6.69B
EBOS GROUP LIMITED Stock EBOS Group Limited
-4.28% 4.02B
MEDIPAL HOLDINGS CORPORATION Stock MediPal Holdings Corporation
+12.80% 3.41B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+6.92% 3.18B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
-13.51% 3.18B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. HLUN B Stock
  4. LUN Stock
  5. Financials Lundbeck